In patients undergoing allogeneic hematopoietic stem cell transplantation, administration of the antiemetic aprepitant significantly increases the clearance of the critical immunosuppressant tacrolimus starting five days after treatment, with the effect lasting for approximately three weeks. The findings, reported in a retrospective observational study published in the Journal of Pharmaceutical Health Care and Sciences, illuminate how aprepitant alters drug metabolism over an extended window following transplantation.
Aprepitant, which includes the intravenous formulation fosaprepitant, is widely prescribed to manage chemotherapy-induced nausea and vomiting during highly emetogenic conditioning regimens. The agent acts as both a moderate inhibitor and an inducer of the cytochrome P450 enzyme CYP3A4. Tacrolimus serves as a vital immunosuppressive therapy to prevent graft-versus-host disease after stem cell transplantation, but because CYP3A4 primarily metabolizes tacrolimus, its systemic availability is sensitive to enzyme modulation.
To clarify the prolonged pharmacokinetic impact of aprepitant on tacrolimus, researchers conducted a retrospective observational evaluation of transplant recipients treated between January 2006 and April 2017. Out of 64 patients initially assessed for eligibility, investigators excluded 16 individuals who had received the antifungal agents voriconazole or itraconazole. The final analytical cohort comprised 48 patients, categorized into 28 individuals in the aprepitant-treated group and 20 individuals in the non-aprepitant control cohort.
During the study protocol, tacrolimus was initiated on day minus one as a continuous intravenous infusion at a baseline rate of 0.03 milligrams per kilogram per day. Clinicians adjusted daily doses through therapeutic drug monitoring to maintain a target blood concentration of 15 nanograms per milliliter. Patients received aprepitant either orally or intravenously for up to five days, starting between day minus eight and day one. To exclude confounding variations in drug bioavailability, patients who transitioned from intravenous to oral tacrolimus were censored at conversion.
Investigators evaluated tacrolimus clearance using the concentration-to-dose ratio as a surrogate metric over a 28-day observation window. Baseline patient characteristics and the concurrent use of moderate CYP3A4 inhibitors were comparable between the aprepitant-treated and untreated groups. Over the first several days following transplantation, specifically from day zero through day four, the concentration-to-dose ratios between the two cohorts showed no meaningful differences, reflecting an initial stability prior to enzymatic changes.
In the aprepitant group, the concentration-to-dose ratio declined from day five to day ten and remained suppressed for approximately three weeks before recovering to day five levels by day 28. Measurements on day 10 plus or minus one and day 20 plus or minus one revealed significantly lower concentration-to-dose values in the aprepitant group compared with controls, reaching statistical significance at P less than 0.01. Correspondingly, tacrolimus dosing requirements in the aprepitant cohort rose from around day five, reaching roughly 30 percent above day four levels between days 10 and 25 before decreasing.
The extended three-week duration of induction may be reinforced by concomitant fluconazole administration or the prolonged elimination half-life of tacrolimus itself.
Subject of Research: Aprepitant effects on tacrolimus pharmacokinetics after stem cell transplantation
Article Title: Long-term effects of aprepitant on tacrolimus pharmacokinetics in allogeneic hematopoietic stem cell transplantation
Article References: Hitachi-Yuzawa, K., Oriyama, T., Yamamoto, T., Ohno, Y., Honda, A., Kurokawa, M., & Takada, T. (2026). Long-term effects of aprepitant on tacrolimus pharmacokinetics in allogeneic hematopoietic stem cell transplantation. Journal of Pharmaceutical Health Care and Sciences. https://doi.org/10.1186/s40780-026-00639-2
Image Credits: AI Generated
DOI: 10.1186/s40780-026-00639-2
Keywords: aprepitant, tacrolimus, pharmacokinetics, allogeneic hematopoietic stem cell transplantation, CYP3A4 induction, therapeutic drug monitoring, graft-versus-host disease, fosaprepitant, concentration-dose ratio, stem cell transplantation, drug clearance, fluconazole, immunosuppressive therapy, antiemetics, cytochrome P450, intravenous infusion, dose escalation
News Source: Drew Townsend. (November 17, 2026). Aprepitant Increases Tacrolimus Clearance for Three Weeks After Stem Cell Transplantation. Scienmag.



